SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-20-070904
Filing Date
2020-06-08
Accepted
2020-06-08 17:04:01
Documents
5
Period of Report
2020-06-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2022015d1_8k.htm 8-K 44456
2 EXHIBIT 10.1 tm2022015d1_ex10-1.htm EX-10.1 81640
3 EXHIBIT 10.2 tm2022015d1_ex10-2.htm EX-10.2 85016
4 EXHIBIT 99.1 tm2022015d1_ex99-1.htm EX-99.1 12008
5 GRAPHIC image_001.jpg GRAPHIC 4192
  Complete submission text file 0001104659-20-070904.txt   230632
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 2161401 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 20949759
SIC: 2836 Biological Products, (No Diagnostic Substances)